Please read the instructions carefully and use under the guidance of a physician.
[Drug name]
English name: Celecoxib Capsules

[Ingredients]
The active ingredient of this product is celecoxib. Its chemical name is: 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.

Chemical structural formula: 
Molecular formula: C₁₇H₁₄F₃N₃O₂S
Molecular weight: 381.38

[Description]
This product is a hard capsule containing white powder.

【Indications】
Celecoxib is indicated for:
1)For relief of the signs and symptoms of osteoarthritis (OA).
2)For relief of the signs and symptoms of rheumatoid arthritis (RA) in adults.
3)For the management of acute pain (AP) in adults.
4)For relief of the signs and symptoms of ankylosing spondylitis.

[Specification]
0.2g

[Dosage and Administration]

Before deciding to use celecoxib, the potential benefits and risks of celecoxib and other treatment options should be carefully considered. The lowest effective dose should be used for the shortest duration consistent with the treatment goals for each individual patient (see [Warnings and Precautions]).

For osteoarthritis and rheumatoid arthritis, the lowest dose of celecoxib should be determined based on individual patient needs. The timing of food intake does not affect the dosing of this product.

Osteoarthritis (OA):

The recommended dose of celecoxib for osteoarthritis is 200 mg once daily or 100 mg twice daily, administered orally.

Rheumatoid Arthritis (RA):

The recommended dose of celecoxib for rheumatoid arthritis is 100 mg to 200 mg twice daily, administered orally.

Acute Pain (AP):

The recommended dose for the management of acute pain is 400 mg on Day 1 as the initial dose, with an optional additional 200 mg if needed, followed by 200 mg twice daily as required thereafter.

Ankylosing Spondylitis (AS):

The recommended dose of this product for the treatment of ankylosing spondylitis is 200 mg daily, administered as a single dose (once daily) or divided into two doses (twice daily). If no response is observed after 6 weeks of treatment, the dose may be increased to 400 mg daily. If a response is still not achieved after 6 weeks of treatment at 400 mg daily, alternative therapeutic options should be considered.